XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, wishes to clarify that the Company’s common shares were halted on both the TSX Venture Exchange (the “TSXV”) and the Canadian Securities Exchange (the “CSE”) to finalize the de-listing procedures required on the CSE. The common shares will be de-listed from the CSE at close of market today and the common shares will re-commence trading tomorrow, Friday, November 5, on the TSXV under the trading symbol XRTX.
Shareholders are not required to exchange their share certificates or take any other action in connection with the TSXV listing, as there will be no change in the CUSIP for the common shares.
About XORTX Therapeutics Inc.
XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney injury associated with Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX Therapeutics is available at www.xortx.com.
For further information, please contact:
| Allen Davidoff, CEO | Nick Rigopulos, Director of Communications |
| This email address is being protected from spambots. You need JavaScript enabled to view it. or +1 403 455 7727 | This email address is being protected from spambots. You need JavaScript enabled to view it. or +1 617 901 0785 |
| Dr. David Sans, Head of Corporate Development in New York City | |
| This email address is being protected from spambots. You need JavaScript enabled to view it. or +1 347 573 0541 | |
The TSX Venture Exchange and Nasdaq have neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
| Last Trade: | US$0.87 |
| Daily Change: | 0.0067 0.78 |
| Daily Volume: | 12,473 |
| Market Cap: | US$3.290M |
May 19, 2025 April 28, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
